Pharmacological subgroup
R03A – INHALATIVE SYMPATHOMIMETIKA
7Decisions
15Patient groups
Added benefit by patient group
- Considerable1
- Minor4
- Not proven9
- Lesser benefit1
Subgroups
Decisions, newest first
- 2021-02-04Enerzair BreezhalerIndacaterol/Glycopyrronium/MometasonNot proven
- 2019-05-02Trelegy ElliptaFluticasonfuroat/Umeclidinium/VilanterolNot proven
- 2018-08-16Trelegy ElliptaFluticasonfuroat/Umeclidinium/VilanterolNot proven
- 2016-02-04Spiolto Respimat Olodaterol/TiotropiumMinor: 1 of 2 patient groupsLesser benefit: 1 of 2 patient groups
- 2015-07-16Brimica GenuairFormoterol/AclidiniumbromidConsiderable: 1 of 4 patient groupsMinor: 1 of 4 patient groupsNot proven: 2 of 4 patient groups
- 2015-01-08Anoro ElliptaUmeclidinium/VilanterolNot proven: 2 of 2 patient groups
- 2014-05-08Ultibro BreezhalerIndacaterol/GlycopyrroniumMinor: 2 of 4 patient groupsNot proven: 2 of 4 patient groups
Data status: 2026-10-29